hrp0092p1-389 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Eight Years of Growth Hormone Treatment in a Patient with Schaaf-Yang Syndrome

Juriaans Alicia , Hokken-Koelega Anita

Background/Aims: Schaaf-Yang syndrome (SYS) is a rare disorder caused by a truncating mutation in the gene MAGEL2, located in the Prader-Willi critical region on chromosome 15. SYS is characterized as a Prader-Willi-like (PWL) disorder, with neonatal hypotonia, feeding problems in early infancy and intellectual disability, obesity and behavioral problems throughout childhood. In this case report we describe a 15-year-old girl, receiving GH treatment since age ...

hrp0095p1-510 | Growth and Syndromes | ESPE2022

Temple syndrome: clinical findings and body composition

Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is an imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder and phenotypic features include pre- and postnatal growth retardation, hypotonia, feeding difficulties, precocious puberty, short stature and truncal obesity.Methods: Thi...

hrp0094p2-294 | Growth and syndromes (to include Turner syndrome) | ESPE2021

The spectrum of the Prader-Willi-like pheno- and genotype

Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita ,

Background/aims: Prader-Willi syndrome (PWS) is a rare genetic syndrome, caused by the loss of expression of the paternal chromosome 15q11-q13 region. Over the past years, many cases of patients with characteristics similar to PWS, but without the typical genetic aberration of the 15q11-q13 region, have been described. These patients are often labelled as Prader-Willi-like (PWL). PWL is an as-yet poorly defined syndrome, potentially affecting a significant num...

hrp0095p1-310 | Growth and Syndromes | ESPE2022

The Prader-Willi phenotype and atypical 15q11.2-q13 deletions

Grootjen Lionne , Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita

Introduction: Prader-Willi syndrome (PWS) is a rare genetic disorder resulting from the lack of expression of the PWS region (locus q11-q13) on the paternally derived chromosome 15. Either a paternal deletion of the PWS region (50%), a maternal uniparental disomy (mUPD; 43%), an imprinting defect (4.1%) or translocation (<1%) can lead to PWS. Deletions are almost always de novo and manifest either as a large type I or a smaller type II deletion. In more rar...

hrp0095p1-505 | Growth and Syndromes | ESPE2022

The effects of one year of growth hormone treatment on growth and body composition in patients with Temple syndrome

Juriaans Alicia , Trueba-Timmermans Demi , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is a rare imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder. Some patients with TS14 are treated with growth hormone (GH). However, evidence for the effectiveness of GH-treatment in patients with TS14 is very limited.Methods: ...

hrp0095p1-299 | GH and IGFs | ESPE2022

Three years of growth hormone (GH) treatment in young adults with PWS previously treated with GH during childhood: Effects on cognitive functioning

Trueba - Timmermans Demi , Mahabier Eva , Grootjen Lionne , Juriaans Alicia , Hokken - Koelega Anita

Introduction: Most patients with Prader-Willi syndrome (PWS) have a mild to moderate cognitive impairment. Growth hormone (GH) treatment has positive short- and long-term effects on cognition in children with PWS. Few studies, however, have investigated the effects of GH on cognitive functioning in adults with PWS.Objective: To investigate the effects of 3 years GH treatment on cognitive functioning in young adults with ...

hrp0089p1-p212 | Pituitary, Neuroendocrinology and Puberty P1 | ESPE2018

Real-World Safety Data in a Cohort of Children with Noonan Syndrome Treated with GH: Final Results from NordiNet International Outcome Study (IOS) and ANSWER Program

Juliusson Petur Benedikt , Dahlgren Jovanna , Abuzzahab M Jennifer , Pedersen Birgitte Tonnes , Roehrich Sebastian , Romano Alicia

Objectives: Current safety data do not indicate an association of GH therapy with increased risk for development/progression of tumours, or worsening of congenital cardiac conditions in individuals with Noonan syndrome (NS); however, data are limited. This report describes real-world safety data on GH therapy in paediatric patients with NS.Methods: Two complementary non-interventional, multicentre studies, NordiNet IOS (NCT00960128) and ANSWER Program (N...

hrp0082p1-d2-43 | Bone | ESPE2014

Study of Mineral and Bone Metabolism in Pediatric Patients with Inflammatory Bowel Disease

Aguilar-Quintero Maria , Caballero-Villarraso Javier , Canete Maria Dolores , Romero-Urrutia Alicia , Canete Ramon

Introduction: Knowledge of changes in bone-mineral metabolism in patients with inflammatory bowel disease (IBD) is of particular interest, since in many patients bone metabolic disease is an epiphenomenon of the underlying pathology. Impaired bone mineralisation and diminished spinal bone mineral density (BMD) are reported in children with IBD, together with increased incidence of vertebral fracture. The short- and long-term implications of reduced BMD are especially important...

hrp0082p1-d1-139 | Growth | ESPE2014

Functional Characterization of Three Novel Mutations in the IGF1R Gene

Juanes Matias , Guercio Gabriela , Marino Roxana , Berensztein Esperanza , Ciaccio Marta , Gil Silvia , Rivarola Marco A , Belgorosky Alicia

Background: IGF1R gene mutations have been associated with varying degrees of intrauterine and postnatal growth retardation, and microcephaly. We have previously reported three novel variants in the IGF1R gene: de novo p.Arg1256Ser, de novo p.Asn359Tyr and p.Tyr865Cys (ENDO 2013, OR20-2).Aim: To characterize the functional effects of the novel IGF1R gene allelic variants.Methods: In ...

hrp0082p2-d3-614 | Turner Syndrome | ESPE2014

Aortic Dilation in a Large Cohort of Paediatric and Young Adult Patients with Turner Syndrome

Geniuk Nadia , Vaiani Elisa , Rizzi Ana , Guercio Gabriela , Warman Monica , Michelli Diego , Rivarola Marco , Belgorosky Alicia

Background: Aortic dilation (AD) occurs in Turner syndrome (TS) increasing the risk of aortic dissection at all ages. There are no current guidelines on what specific aortic diameter measurement should provoke concern in pediatric TS. Because of their small stature, an aortic size index (ASI) has been proposed to normalize the ascending aorta (AA) to body size in young adultsÂ’ with TS. However, a more reliable index has been also proposed: the ratio of vascular diameter t...